Lymphomas diffuse large-cell lymphoma

H8. Horst, E., Meijer, C., Radaszkiewicz, T., Ossekoppele, G., Van Krieken, J., and Pals, S. T., Adhesion molecules in the prognosis of diffuse large cell lymphoma expression of a lymphocyte homing receptor (CD44), LFA-1 (CDIIa/18) and ICAM-1 (CD54). Leukaemia 4, 595-599 (1990). [Pg.162]

IL-14. IL-14 can be produced by aggressive intermediate (diffuse large cell) lymphomas of B cell-type non-Hodgkin s lymphoma (NHL-B) in patients with lymphomatous effusions. The autocrine or paracrine production of IL-14 may play a significant role in the rapid proliferation of aggressive NHL-B (F4). [Pg.4]

Diffuse Large-Cell Lymphoma (DLCL). These clinically aggressive tumors may present in lymph nodes or in extranodal sites (Hll). They can occur in patients of all ages (Al, A14). Most cases arise de novo however, some may represent transformation from a low-grade lymphoma. [Pg.318]

Therapeutic modalities in cancer treatment may involve surgery, radiation, and/or chemotherapy. The objectives of cancer chemotherapy include (1) cure, (2) reduction in tumor size, and (3) prolongation of life. At the present time, approximately 50 percent of patients with cancer can be cured, with drug treatment estimated to contribute in 17 percent of cases. Cancer chemotherapy can be curative in testicular cancer, diffuse large cell lymphoma, Hodgkin s disease, choriocarcinoma, certain childhood tumors (acute lymphoblastic leukemia, Burkitt s lymphoma, Wilms tumor, and embryonal rhabdomyosarcoma). Certain cancers are more resistant to chemotherapy than others (e.g., lung and colon). [Pg.177]

Mohammad RM, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-l. Clin. Cancer Res. 2007 13 2226-2235. [Pg.181]

Diffuse large-cell lymphoma CHOP cyclophosphamide + doxorubicin + vincristine (Oncovin) - prednisolone... [Pg.607]

Jackson DV Jr, Craig JB, Spurr CL, White DR, Muss HB, Cruz JM, Richards F, Powell BL. Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma. Cancer Invest 1990 8(1) 7-12. [Pg.1032]

Mohammad, R. M., Wang, S., Aboukameel, A., Chen, B., Wu, X., Chen, J., and Al-Katib, A. (2005). Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol. Cancer Ther. 4,13-21. [Pg.257]

Acute nonlymphocytic (myelogenous) leukemia Diffuse large cell lymphoma Testicular cancer... [Pg.2290]

NHL has lead to several international projects to develop prognostic models in the most common types of NHLs—diffuse large cell lymphomas and follicular lymphomas. The International Non-Hodgkin s Lymphoma Prognostic Lactors Project was based on more than 2,000 patients with diffuse aggressive lymphomas treated with... [Pg.2451]

Doggett RS, Wood GS, Horning S, et al. The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol. 1984 115(2) 245-252. [Pg.186]

Donoghue S, Baden HS, Lauder 1, et al. Immunohistochemical localization of caspase-3 correlates with clinical outcome in B-cell diffuse large-cell lymphoma. Cancer Res. 1999 59(20) 5386-5391. [Pg.187]

Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis A clinicopathologic study of 60 cases. Am J Surg Pathol. 1986 10 176-191. [Pg.365]

Diffuse large cell lymphoma (NHL), and Hodgkin s disease... [Pg.459]

Pasqualucci, L., Neumeister, P., Goossens, T., Nanjangud, G., Chaganti, R. S., Kuppers, R., and Dalla-Favera, R. (2001). Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341-346. [Pg.333]

Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar E, Kucuk O (2003) Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther 2 1361-1368... [Pg.2249]

A 63-year-old woman with septic shock received voriconazole to treat invasive pulmonary aspergillosis (IPA). She had prolonged neutropenia due to chemotherapy Jbr a diffuse large-cell lymphoma. Multiple episodes spontaneous bradycardia (20-40 beats/min) ensued. The heart rate was normalised ffter voriconazole was changed to caspofungin. [Pg.384]

LL, a 47-year-old man, was diagnosed with high-risk diffuse large cell B-cell non-Hodgkin s lymphoma (NHL) 12 months ago. LL had a complete response to his initial treatment of six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). LL is participating in a clinical trial and is randomized to receive a myeloablative autologous HCT TBI days 8 to 5, etoposide day 4, rest day 3, cyclophosphamide day 2, rest day 1, with infusion of autologous PBPC on day 0. [Pg.1452]

CLL/SLL, Chronic lymphocytic leukemia/small lymphocytic lymphoma MCL, mantle cell lymphoma FL, follicular lymphoma MZL/MALT, marginal zone lymphoma/mucosa-associated lymphoid tisuse lymphoma SMZL, splenic marginal zone lymphoma HCL, hairy cell leukemia DLCL, diffuse large-cell lymphoma PCM, plasma cell myeloma BCL-1, cyclin D1 FDC MW, Follicular dendritic cell meshworks CK, cytokeratin LELs, lymphoepitheilal lesions. [Pg.311]

Depsipeptide II Refractory mantle cell or diffuse large cell non-Hodgkin s lymphoma NCI/MAYO... [Pg.477]

Haln T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin s lymphoma an evidence-based review. Biol Blood Marrow Transplant 2001 7 308-331. [Pg.2465]

Davis RE, Dorfman RF, Warnke RA. Primary large-cell lymphoma of the thymus a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. Hum Pathol. 1990 21(12) 1262-1268. [Pg.187]

Trump DL, Mann RB. Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement A poor prognostic subset of patients with non-Hodgkin s lymphoma. Cancer. 1982 50 277-282. [Pg.366]

FIGURE 18.33 Lymphoma of the ovary. This diffusely infiltrative tumor proved to be a large cell lymphoma of B-cell type an im-munostain for CD20 a B-cell marker, shows strong staining of the... [Pg.731]

Adenocarcinoma of breast, colon, biliary tract, pancreas, lung, ovary, skin papillary transitional cell carcinoma of bladder, anaplastic large cell lymphoma, diffuse large B-cell lymphoma... [Pg.67]

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, et al. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cane Biol Ther 2012 13(2) 114—22. [Pg.399]

In the first dose escalating and exploratory phase 1 study, ibrutinib showed antitumor activity in multiple B-ceU cancers. 56 patients with relapsed/refractory CLL/SLL and B-cell NHLs, such as MCL, folhcular lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, and WM, were enrolled. The overall response rate was 60%, including 16% complete response. The median progression-free survival was 13.6 months and most adverse events were grades 1 and 2. Btk was completely occupied at doses 2.5 mg/kg and above as demonstrated by probe (2) competition assay of peripheral blood mononuclear cell samples collected from patients. [Pg.161]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...